70 Participants Needed

ARC101 for Cancer

Recruiting at 4 trial locations
VC
Overseen ByVP Clinical Operations
Age: 18+
Sex: Any
Trial Phase: Phase 1
Sponsor: Third Arc Bio
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

What is the purpose of this trial?

This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of ARC101 in patients with advanced cancer.

Eligibility Criteria

This trial is for adults with advanced solid tumors, specifically ovarian, testicular or other cancers positive for Claudin 6. Participants must have a condition that can be measured by medical imaging and should be relatively active and able to care for themselves (ECOG status 0-1). They also need to have their major organs functioning well.

Inclusion Criteria

My cancer can be measured or evaluated by standard criteria.
My cancer is advanced or has spread and tests positive for Claudin 6.
I am fully active or can carry out light work.
See 1 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Dose Escalation

ARC101 will be administered in escalating doses, with each dose escalation cohort assessing toxicity 21 days after the initial dose

21 days per cohort

Dose Expansion

ARC101 will be administered at recommended phase 2 dose(s)

Approximately 1 year

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

  • ARC101
Trial Overview ARC101 is the focus of this first-in-human study. It's being tested on patients with advanced cancer to see how safe it is, how the body reacts to it (pharmacokinetics), if it causes any side effects (tolerability), and whether it helps reduce tumor size or spread (antitumor activity).
Participant Groups
2Treatment groups
Experimental Treatment
Group I: Dose Expansion CohortsExperimental Treatment1 Intervention
ARC101 will be administered at recommended phase 2 dose(s).
Group II: Dose Escalation CohortsExperimental Treatment1 Intervention
ARC101 will be administered in escalating doses, with each dose escalation cohort assessing toxicity 21 days after the initial dose.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Third Arc Bio

Lead Sponsor

Trials
1
Recruited
70+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security